---
layout: minimal-medicine
title: Pralsetinib
---

# Pralsetinib
### Generic Name
Pralsetinib

### Usage

Pralsetinib is a targeted cancer therapy, specifically a kinase inhibitor.  Its primary use is in treating adult patients with metastatic non-small cell lung cancer (NSCLC) that's positive for rearranged during transfection (RET) gene fusions, as confirmed by an FDA-approved test.  Importantly, it's also approved for treating advanced or metastatic RET fusion-positive thyroid cancer in adults and pediatric patients (aged 12 and older) needing systemic therapy, particularly those who haven't responded to radioactive iodine (if appropriate).  Finally, pralsetinib treats advanced or metastatic RET-mutant medullary thyroid cancer in adults and pediatric patients (aged 12 and older) who require systemic therapy.  The choice of pralsetinib depends on the presence of a RET gene fusion (for lung and thyroid cancers) or a RET gene mutation (for medullary thyroid cancer).

### Dosage

**Adults:** The usual dose for all approved indications is 400 mg once daily (OD) orally, continuing until disease progression or unacceptable toxicity.

**Pediatric Patients (≥12 years):** The dose is the same as for adults for RET fusion-positive and RET-mutant medullary thyroid cancer.  Pralsetinib's safety and effectiveness haven't been established in children under 12 years old.

**Dosage Adjustments:**  Dose adjustments are necessary based on several factors.  For hepatic impairment, mild impairment doesn't require adjustment, but moderate or severe impairment requires careful consideration and potential dose reduction or discontinuation as per the physician's guidance. Renal impairment also requires individual assessment by the healthcare provider and may not necessitate dose changes in all cases.  Dosage reduction is recommended for various toxicities like hemorrhagic events, hypertension, and pulmonary toxicity (interstitial lung disease or pneumonitis), with potential discontinuation in severe cases.  Specific guidelines regarding co-administration with certain CYP3A inhibitors and inducers are also provided in the complete prescribing information.  Always follow your healthcare professional's guidance for dosage adjustments.


### Side Effects

**Common Side Effects (>10%):**

*   Nervous system: Dizziness, fatigue, headache, peripheral neuropathy
*   Cardiovascular: Edema, hypertension
*   Dermatologic: Skin rash
*   Endocrine & Metabolic: Changes in serum levels of albumin, calcium, magnesium, phosphate, and sodium
*   Gastrointestinal: Abdominal pain, constipation, decreased appetite, diarrhea, dysgeusia (altered taste), nausea, stomatitis (mouth sores), xerostomia (dry mouth)
*   Hematologic & Oncologic: Decreased hemoglobin, neutrophils, and platelets; lymphocytopenia (low lymphocyte count); tumor lysis syndrome
*   Hepatic: Increased liver enzyme levels (ALT, ALP, AST, bilirubin)
*   Neuromuscular & Skeletal: Increased creatine phosphokinase, musculoskeletal pain
*   Renal: Increased serum creatinine
*   Respiratory: Cough, dyspnea (shortness of breath), pneumonia
*   Other: Fever

**Less Common, but Serious Side Effects (1-10% or less frequently reported):**

*   Hemorrhage
*   Severe hepatotoxicity
*   Sepsis
*   Pneumonitis
*   Syncope (fainting)
*   Vomiting
*   Leukopenia (low white blood cell count)


If you experience any side effects, especially severe ones, contact your healthcare provider immediately.

### How it Works

Pralsetinib is a tyrosine kinase inhibitor.  It works by selectively blocking the activity of RET (rearranged during transfection) protein kinases.  These kinases are frequently involved in the development and growth of certain cancers. By inhibiting RET, pralsetinib interferes with the cancer cells' signaling pathways, ultimately hindering their growth and spread. It also inhibits other kinases, though the clinical significance of this is not fully understood.


### Precautions

*   **Contraindications:**  No specific contraindications are listed in the manufacturer's labeling. However,  individual assessment is always crucial.
*   **Drug Interactions:** Pralsetinib can interact with several other medications, particularly those affecting the CYP3A4 and P-glycoprotein systems. Co-administration with strong CYP3A4 inhibitors and inducers requires careful management and dose adjustments as directed by your doctor.
*   **Pregnancy and Breastfeeding:** Pralsetinib is known to be harmful to the developing fetus. Women of reproductive potential should use effective non-hormonal contraception during treatment and for two weeks afterward. Breastfeeding is not recommended during treatment and for one week after the last dose.
*   **Other Precautions:** Patients should be monitored for bone marrow suppression, hemorrhagic events, hepatotoxicity, hypertension, pulmonary toxicity, tumor lysis syndrome (especially in medullary thyroid cancer), impaired wound healing, and other potential adverse reactions.

### FAQs

*   **Can I eat while taking Pralsetinib?**  No, it's recommended to take Pralsetinib on an empty stomach – at least two hours before a meal and one hour after.
*   **What should I do if I miss a dose?** Take the missed dose as soon as possible on the same day, then resume your regular schedule.
*   **How should I store Pralsetinib?** Follow the storage instructions provided on the medication label.
*   **How long does it take to see results?** The time to see effects varies by patient and disease.  Consult your oncologist for personalized timelines and expectations.
*   **Is Pralsetinib safe for everyone?**  Pralsetinib has potential side effects and is not suitable for everyone.  Your doctor will conduct a thorough assessment of your medical history before prescribing it.

**Disclaimer:** This information is intended for educational purposes only and does not constitute medical advice. Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.  This summary is based on publicly available information and may not be exhaustive.  Always refer to the official prescribing information for the most complete and up-to-date details.
